Revvity to announce Q2 2026 results on August 4

0 min read     Updated on 08 Jul 2026, 07:13 PM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Revvity will release its Q2 2026 financial results on August 4, 2026, before market open, followed by a conference call at 7:30 a.m. ET hosted by CEO Prahlad Singh and CFO Max Krakowiak. The company reported 2025 revenue of $2.9 billion and serves customers in over 160 countries.

powered bylight_fuzz_icon
45063802

*this image is generated using AI for illustrative purposes only.

Revvity will release its second quarter 2026 financial results before market open on Tuesday, August 4, 2026. The company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.

Investors can access the live audio webcast through the Investors section of Revvity's website. The company provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure.

Company Overview

Revvity reported 2025 revenue of $2.9 billion and employs approximately 11,000 people. The company serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments in more than 160 countries. It is part of the S&P 500 index.

Key Details

Event Date/Time
Q2 2026 Results Release Tuesday, August 4, 2026 (before market open)
Conference Call Tuesday, August 4, 2026 at 7:30 a.m. ET
Hosts Prahlad Singh (President and CEO), Max Krakowiak (CFO)

What strategic initiatives will Revvity prioritize in the second half of 2026 to drive growth?

How might Revvity's performance in Q2 2026 impact its position within the S&P 500?

What are the expected market reactions to Revvity's Q2 2026 financial results?

like16
dislike

Evercore ISI raises Revvity price target to $125

0 min read     Updated on 07 Jul 2026, 01:13 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Evercore ISI Group analyst Vijay Kumar maintained an Outperform rating on Revvity and raised the price target to $125 from $110.

powered bylight_fuzz_icon
44912622

*this image is generated using AI for illustrative purposes only.

Evercore ISI Group analyst Vijay Kumar has maintained an Outperform rating on Revvity while raising the price target for the stock. The new target of $125 represents an increase from the previous level of $110.

Rating and Price Target Details

The revision reflects a positive outlook on the company's performance. The following table summarizes the updated analyst action:

Metric Value
Rating Outperform
Previous Price Target $110
New Price Target $125

Revvity is listed on the NYSE under the ticker symbol RVTY.

What specific factors are driving the increased optimism for Revvity's future performance?

How might this price target adjustment influence investor sentiment towards the healthcare diagnostics sector?

What upcoming milestones or product launches could further validate the raised price target?

like20
dislike

More News on Revvity Inc

Must Read Next

Earnings

Corporate Actions

Stocks